WHEN TWO INVESTIGATIONS REACH THE SAME CONCLUSION.

THE UNANSWERED QUESTIONS SURROUNDING WELLBEING INTERNATIONAL FOUNDATION LTD

Independent investigations are at their strongest when they arrive at the same destination without working together.

Over the past year, our own investigation into Wellbeing International Foundation has examined the company's marketing, corporate structure, treatment claims, addresses, and patient recruitment methods. During that process, we became aware of a separate newspaper investigation that examined many of the same issues from a different direction.

What is remarkable is not where the two investigations differ.

It is where they agree.

The newspaper investigation focused heavily on covert recordings, expert scientific analysis and legal opinion. It questioned claims surrounding extracellular vesicle therapies, the use of testimonials, and statements suggesting benefits for conditions including Parkinson's disease and Multiple Sclerosis.

Experts interviewed during that investigation expressed serious concerns about the scientific evidence supporting such claims and questioned whether vulnerable patients could distinguish between established medicine and experimental concepts.

Our own investigation followed a different path.

Rather than beginning with treatment claims, we started with the company itself.

We examined the corporate structure behind Wellbeing International Foundation, including its links to Bermuda, the addresses used in promotional material, and the locations presented to patients as part of the company's international operation.

What we found raised further questions.

The Bermuda address associated with the organisation appears to be a multi-occupancy office facility rather than a dedicated treatment centre. Likewise, investigations into the company's Harley Street presence suggest the location functions primarily as a consulting address rather than a specialist regenerative medicine facility operated by the company itself.

These findings do not automatically imply wrongdoing.

However, they do raise an obvious question:

Where exactly is the treatment infrastructure that patients might reasonably expect from a company promoting advanced regenerative therapies costing tens of thousands of pounds?

The newspaper investigation raised concerns regarding scientific evidence.

Our investigation raises questions regarding operational transparency.

Taken together, these concerns create a wider picture that regulators may struggle to ignore.

Both investigations identified extensive use of scientific terminology that would be difficult for the average patient to independently verify. Terms such as extracellular vesicles, secretomes, regenerative signalling and cellular communication feature heavily throughout promotional materials.

Yet despite the complexity of the language, a simple question remains.

Can the company demonstrate robust clinical evidence supporting the claims being made to patients?

That question appears repeatedly throughout both investigations.

A second area of overlap concerns accountability.

The newspaper investigation highlighted expert criticism regarding regulation and oversight. Our investigation found a corporate structure spanning multiple jurisdictions, including offshore entities and addresses that appear administrative rather than clinical in nature.

Again, these arrangements are not unlawful.

But they can make it significantly more difficult for patients to understand who is responsible, where treatments originate, and which regulatory authority ultimately oversees the activity.

Perhaps the most important common finding is this:

Both investigations encountered a significant gap between marketing language and independently verifiable evidence.

For patients facing chronic illness, degenerative disease or life-changing diagnoses, that distinction matters enormously.

Hope is powerful.

But hope should never replace evidence.

As regulators around the world continue to examine the rapidly growing market for stem cell and extracellular vesicle therapies, the unanswered questions surrounding Wellbeing International Foundation remain.

And when two independent investigations reach many of the same conclusions, those questions become harder to dismiss.

The public deserves clear answers.

Patients deserve transparency.

And extraordinary medical claims should always be supported by extraordinary evidence.